At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,299 enrolled
Drug / intervention
no interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
In Brief
An observational study evaluating no intervention for Breast Cancer. Completed, enrolled 1,299 participants across 1 site.
Detailed Summary
About a half of HER2-negative breast cancer show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC samples. Patients with matched primary and relapse BC samples were included. 1299 patients were included.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartJan 2021
Primary CompletionJun 2022
First PostedAug 2022
TodayJul 2026
First PostedAug 22, 2022
Enrollment StartJan 1, 2021
Primary CompletionJun 1, 2022
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 3.9 years ago
Interventions
no interventionother
no intervention was needed